Clinical trials to combat reproductive cancers in Australia

The Australian Government is investing up to $15 million in targeted clinical trials to improve treatments and discover cures for reproductive and gynaecological cancers such as ovarian, cervical and fallopian cancer.

An estimated 6,454 Australian women will be diagnosed with a gynaecological cancer this year, and 19,871 women will live their lives with these devastating diseases.

The round will also call for trials into testicular cancer, the second most common cancer in young men (aged 18 to 39).

These cancers represent a significant burden of disease in the Australian population.

The funding, from the Medical Research Future Fund (MRFF) Rare Cancers, Rare Diseases and Unmet Need (RCRDUN) Clinical Trials Program, will support projects of up to three years to drive new ideas and make new discoveries to improve quality of life and survival rates for Australians with these cancers.

The RCRDUN program has a focus on under-researched health priorities and conditions where there are limited effective treatment options and a breakthrough is needed.

This grant round will open on 14 October 2019 and close on 14 February 2020.

More information, including the grant guidelines, will be available on GrantConnect.

You may also like Highlights from Accelerating Australia’s Life Sciences Innovation Expo